# ModernGraham Valuation

## **Company Name:**

Company Ticker TECH Date of Analysis **BIO-TECHNE** Corp



## Stage 1: Is this company suitable for the Defensive Investor or the Enterprising Investor?

7/16/2017

Defensive Investor; must pass 6 out of the following 7 tests.

| <ol> <li>Adequate Size of the Enterprise</li> </ol> | Market Cap > \$2Bil  | \$4,287,433,575 | Pass |
|---|--|-----------------|------|
| 2. Sufficiently Strong Financial Condition          | Current Ratio > 2  | 2.15            | Pass |
| 3. Earnings Stability                               | Positive EPS for 10 years prior  |                 | Pass |
| 4. Dividend Record                                  | Dividend Payments for 10 years prior   |                 | Fail |
| 5. Earnings Growth                                  | Increase of 33% in EPS in past 10<br>years using 3 year averages at<br>beginning and end | -5.86%          | Fail |
| 6. Moderate PEmg Ratio                              | PEmg < 20  | 43.41           | Fail |
| <ol><li>Moderate Price to Assets</li></ol>          | PB Ratio < 2.5 OR PB*PEmg < 50   | 4.76            | Fail |

Enterprising Investor; must pass 4 out of the following 5 tests, or be suitable for the Defensive Investor.

| 1. Sufficiently Strong Financial Condition | Current Ratio > 1.5            | 2.15 Pass |
|--|--------------------------------|-----------|
| 2. Sufficiently Strong Financial Condition | Debt to NCA < 1.1              | 2.10 Fail |
| 3. Earnings Stability                      | Positive EPS for 5 years prior | Pass      |
| 4. Dividend Record                         | Currently Pays Dividend        | Pass      |
| 5. Earnings Growth                         | EPSmg greater than 5 years ago | Fail      |
|  | Score                          |           |

#### Suitability

| Defensive    | No |
|--------------|----|
| Enterprising | No |

#### Stage 2: Determination of Intrinsic Value

|            | EPSmg                       |            | \$2.65   |
|------------|-----------------------------|------------|----------|
|            | MG Growth Estimate          |            | -1.76%   |
|            | MG Value                    |            | \$13.19  |
|            | MG Value based on 3% Growth |            | \$38.49  |
|            | MG Value based on 0% Growth |            | \$22.56  |
|            | Market Implied Growth Rate  |            | 17.46%   |
| MG Opinion |                             |            |          |
|            | Current Price               |            | \$115.25 |
|            | % of Intrinsic Value        |            | 873.49%  |
|            | Opinion                     | Overvalued |          |
|            | MG Grade                    | F          |          |


## Stage 3: Information for Further Research

| Net Current Asset Value (NCAV)          | -\$8.52 |
|---|---------|
| Graham Number                           | \$34.03 |
| PEmg                                    | 43.41   |
| Current Ratio                           | 2.15    |
| PB Ratio                                | 4.76    |
| Current Dividend                        | \$1.28  |
| Dividend Yield                          | 1.11%   |
| Number of Consecutive Years of Dividend |         |
| Growth                                  | 8       |

Useful Links:

ModernGraham tagged articles Google Finance Yahoo Finance GuruFocus Morningstar MSN Money Seeking Alpha SEC Filings

| EPS History      |        | EPSmg History                        |                 |
|------------------|--------|--------------------------------------|-----------------|
| Next Fiscal Year |        |                                      |                 |
| Estimate         |        | Next Fiscal Year Estimate            | \$2.65          |
| Jun2016          | \$2.80 | Jun2016                              | \$2.91          |
| Jun2015          | \$2.89 | Jun2015                              | \$2.98          |
| Jun2014          | \$3.00 | Jun2014                              | \$3.02          |
| Jun2013          | \$3.05 | Jun2013                              | \$3.01          |
| Jun2012          | \$3.04 | Jun2012                              | \$2.95          |
| Jun2011          | \$3.02 | Jun2011                              | \$2.84          |
| Jun2010          | \$2.94 | Jun2010                              | \$2.66          |
| Jun2009          | \$2.78 | Jun2009                              | \$2.42          |
| Jun2008          | \$2.64 | Jun2008                              | \$2.12          |
| Jun2007          | \$2.15 | Jun2007                              | \$1.78          |
| Jun2006          | \$1.85 | Jun2006                              | \$1.49          |
| Jun2005          | \$1.62 | Jun2005                              | \$1.23          |
| Jun2004          | \$1.27 | Jun2004                              | \$0.99          |
| Jun2003          | \$1.08 | Jun2003                              | \$0.80          |
| Jun2002          | \$0.64 | Jun2002                              | \$0.63          |
| Jun2001          | \$0.80 | Jun2001                              | \$0.59          |
| Jun2000          | \$0.63 | Balance Sheet Information            | 3/1/2017        |
| Jun1999          | \$0.41 | Total Current Assets                 | \$306,042,000   |
| Jun1998          | \$0.39 | Total Current Liabilities            | \$142,200,000   |
| Jun1997          | \$0.28 | Long-Term Debt                       | \$343,637,000   |
|                  |        | Total Assets                         | \$1,533,431,000 |
|                  |        | Intangible Assets                    | \$1,052,431,000 |
|                  |        | Total Liabilities                    | \$625,506,000   |
|                  |        | Shares Outstanding (Diluted Average) | 37,494,000      |





#### Disclaimer:

This valuation is not investment advice. Anyone who is considering making an investment decision should speak to a registered investment advisor.

The author did not hold a position in any company mentioned in this article at the time of publication and had no intention of changing those holdings within the next 72 hours.

#### **Recommended Reading:**

Other ModernGraham posts about the company #N/A

 
 Other ModernGraham posts about related
 LifePoint Health Inc Valuation – Initial Coverage \$LPNT

 Psychemedics Corp Valuation – April 2017 \$PMD
 Community Health Systems Valuation – Initial Coverage \$CYH

 Patterson Companies Inc Valuation – April 2017 \$PDCO
 Luminex Corp Valuation – Initial Coverage \$LMNX

 C R Bard Inc Valuation – March 2017 \$BCR
 LHC Group Inc Valuation – Initial Coverage \$LHCG

 Dentsply Sirona Inc Valuation – Initial Coverage \$LDR
 National Coverage \$LDR

IDEXX Laboratories Inc Valuation - Initial Coverage \$IDXX